interferon - for COVID 19 hospitalized method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.75 [0.21, 2.65]< 161%2 studies (2 / -)67.0 %some concernnot evaluable moderatecrucial-
clinical improvement 2.19 [1.03, 4.67]> 10%1 study (1 / -)97.9 %highnot evaluable lowimportant-
clinical improvement (time to event analysis only) 3.41 [1.33, 8.73]> 10%1 study (1 / -)99.5 %NAnot evaluable important-
clinical worsening 0.44 [0.04, 5.09]< 10%1 study (1 / -)74.4 %some concernnot evaluable moderateimportant-
death or ventilation 0.58 [0.13, 2.65]< 174%2 studies (2 / -)76.0 %highnot evaluable lowimportant-
hospital discharge 1.01 [0.06, 18.30]> 165%2 studies (2 / -)50.2 %some concernnot evaluable moderateimportant-
hospitalization 1.00 [0.02, 51.94]< 10%1 study (1 / -)50.0 %NAnot evaluable important-
PCR-negative conversion (time to event analysis only) 0.31 [0.14, 0.65]> 10%1 study (1 / -)0.1 %some concernnot evaluable moderateimportant-
ventilation 0.29 [0.05, 1.56]< 10%1 study (1 / -)92.5 %NAnot evaluable important-
ICU admission 0.37 [0.14, 1.00]< 10%1 study (1 / -)97.5 %NAnot evaluable non important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 3 pathologies: 95,94,90,91 95, 91, 90